Martin Ostrowski

Ladenburg Thalmann & Co., Inc. (Broker) is the broker/dealer division of Ladenburg Thalmann & Co., Inc., ultimately held by Advisor Group Holdings, Inc. Headquartered in New York City, the firm was founded in 1876 and offers a full suite of capital markets products and services, including proprietary equity research and a fixed-income trading desk. For institutional asset management clients, the firm provides liquidity, execution, high-quality idea-generating research, and access to corporate management teams. Their institutional coverage includes relationships with over asset management companies all over the world. To corporate clients, they bring access to investor capital, broad distribution capabilities and financial markets advisory. Ladenburg Thalmann is a leader in financing growing middle-market public companies across various industry verticals, including Healthcare & Life Sciences, Yield-Oriented Securities (BDCs, REITs, MLPs), Energy, Power & Infrastructure, and Telecom, Media & Technology.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Astellas Venture Management LLC (Astellas Venture Management) is a venture capital subsidiary of Astellas Pharma Inc founded in 2000. The firm is headquartered in San Francisco, California.

Ladenburg Thalmann & Co., Inc. provides investment baking and brokerage services. The firm also provides asset and wealth management, underwriting, alternative investments and advisory services. It serves emerging growth companies and high net worth individuals. The company was founded in 1876 and is headquartered in New York, NY.

Genome Canada provides genomic research services. It connects ideas and people across public and private sectors to find new uses for genomics, invests in large-scale science and technology to fuel innovation,and translates discoveries into applications, new technologies, societal impacts and solutions across key sectors of national importance, including health, agriculture, forestry, fisheries and aquaculture, energy, mining, and the environment. The company was founded in 2000 and is headquartered in Ottawa, Canada.

Goldman Sachs (Asia) LLC (GS-Asia) is the Hong Kong-based brokerage subsidiary of Goldman Sachs Holdings (Hong Kong) Ltd., ultimately owned by The Goldman Sachs Group, Inc. (NYSE: GS), a multinational investment bank and financial services company headquartered in New York City. Founded in 1984, GS-Asia provides market insight, risk management and execution services to institutional clients which includes asset managers, hedge funds, banks and brokerages, pensions, endowments and foundations, corporations, and governments.

Aqumen Biopharmaceuticals KK is a holding company that provides research and development of therapeutic medicines for macular degeneration. It also develops therapeutics for diabetic retinopathy, diabetic nephropathy, adjuvants for ophthalmic surgery, and intraocular drug delivery systems. The firm's products encompass the ILM-Blue and the MembraneBlue-Dual. The company was founded by Kimihiko Fujisawa and Tadahisa Kagimoto on April 11, 2005 and is headquartered in Fukuoka, Japan.

Part of The Goldman Sachs Group, Inc., Goldman Sachs (Cayman) Trust Ltd. is a Caymanian company that provides security brokerage services. The company is based in George Town, Cayman Islands.

Nezu Asia Capital Management Ltd. (Nezu HK) is the alternative investment management subsidiary of Nezu Group S.A.R.L., itself owned by Nezu Group LP in the US. Headquartered in Hong Kong, Nezu HK was founded in 2004 and they provide discretionary investment advisory services to separately managed accounts and a private investment fund, which is open only to certain financially sophisticated and high-net worth individuals and entities.

Part of GSK Plc, GlaxoSmithKline AB is a company that manufactures pharmaceutical products. GlaxoSmithKline AB is based in Solna, Sweden. Founded in 1983.

Geistlich Biomaterials Vertriebsgesellschaft mbH provides natural biomaterials for dental, medical and cosmetic surgery use. The company was founded in 1996 and is headquartered in Baden-Baden, Germany.

Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA.

Nezu Asia Capital Management (Singapore) Pte Ltd. (Nezu Asia SG) is an independent hedge fund manager headquartered in Singapore. Nezu Asia SG manages long/short equity portfolios.

Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada.

Insitut de Recherche en Immunologie et en Cancérologie develops and discovers treatment and therapies for cancers. It also engages in anticancer drug discovery chain. The company was founded in 2003 and is headquartered in Montréal, Canada.

Nezu Master Strategy Feeder Ltd. Operates as a private equity fund. The company is headquartered in Grand Cayman, Cayman Islands.

Redona Therapeutics, Inc.operates as a biotechnology company focused on the modulation of non- RNA (ncRNA) function to treat cancer and other human diseases. It uses small molecules to modulate expression levels of oncogenes and other proteins of significance in disease. The company was founded by George Daley, Richard Gregory, Frank Slack, and Piotr Sliz and is headquartered in Watertown, MA.

Pykus Therapeutics, Inc. engages in the development of a dissolvable intraocular surgical device. It offers novel polymer that provides retinal tamponade. The company was founded by James Stefater and Tomasz Stryjewski and is headquartered in Boston, MA.

Antion Biosciences SA is a Swiss-based biotechnology company that develops universal cell and gene therapy products to treat diseases with significant unmet medical needs. The private company is based in Geneva, Switzerland. The company's proprietary gene silencing and co-expression gene constructs allow for a modular and tunable approach to multiplex engineering of therapeutic cells. Antion aims to develop off-the-shelf therapies with enhanced potency and improved safety to make cell and gene therapies universal and broaden access to these life-changing therapies for all patients. Antion Biosciences was founded by Michael Pepper and Roberto Speck, and the CEO is Marco Alessandrini.

United Immunity Co. Ltd. is a Japanese company that specializes in pipeline nano technology and immunity fusion technology, specifically in the field of cancer immunotherapy. The company is based in Tsu, Japan and was founded in 2017 by Naozumi Harada, who has been the CEO since then. The company's diverse products, including "nano immunotherapy," have shown promising clinical results and research in the treatment of sex cancer. The company is currently recruiting a researcher in the cancer immunotherapy field to analyze the action mechanism of nanotechnology applied cancer evaluation and drug evaluation using immunological methods. The company's focus is on the development of treatment for the cause of cold tumor type cancer through the understanding of tumor-associated macrophages.

Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware.

PowerX, Inc. is a Japanese next-generation energy company that aims to build a new energy grid of renewable energy storage. The company is based in Minato-ku, Japan, and the CEO of the company is Masahiro Ito. The company will construct a large-scale storage battery factory to manufacture and sell battery products that realize the explosive spread of natural energy. The PowerX ship battery is a safe and secure product that uses LFP, which is a safe and long-life battery. The battery can be installed in racks and provided as a large-capacity type of the industry-standard 10 or 20ft container type. With PowerX's large industrial storage battery mega power, businesses can significantly reduce their electricity bills. The company's solution can be introduced right now and will be available for shipping from 2023.